Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
13
×
national blog main
boston blog main
boston top stories
biotech
national top stories
clinical trials
san francisco blog main
boston
new york blog main
san diego blog main
san francisco top stories
new york top stories
san diego top stories
cancer
crispr
indiana blog main
indiana top stories
national
biology
biotechnology
blueprint medicines
boulder/denver blog main
boulder/denver top stories
deals
depression
detroit blog main
detroit top stories
dna sequencing
drugs
dyne therapeutics
editas medicine
fda
george church
healthcare
myotonic dystrophy type 1
raleigh-durham blog main
raleigh-durham top stories
rare disease drugs
rare diseases
What
genetic
13
×
medicines
drug
new
medicine
cancer
dna
fda
ipo
million
raised
rare
ago
approved
bio
biotech
company
cost
diseases
dyne
editing
experimental
gene
low
medical
muscle
oks
research
testing
therapeutics
treatment
year
abbvie
ability
acquire
address
agriculture
aims
akcea
alliance
Language
unset
Current search:
genetic
×
" life sciences "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@techcrunch.com
5 years ago
DNA Script picks up $38.5 million to make DNA production faster and simpler
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@techcrunch.com
5 years ago
XGenomes is bringing DNA sequencing to the masses
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?